Universal Ibogaine Inc.
IBOGF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.86K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $30,861.00 |
|---|---|
| Enterprise Value | $2.89 Million |
| Earnings per Share | $-0.06 |
| Beta | 4.38 |
| Outstanding Shares | 308,610,516 |
Return
| Return on Equity | -542.44% |
|---|---|
| Return on Assets | -36.85% |
| Return on Invested Capital | -36.03% |
Valuation & Multiples
| P/E Ratio | -0.5 |
|---|---|
| PEG | 0.54 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.4 |
| Enterprise Value to EBIT | -4.02 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | 10.96 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Universal Ibogaine Inc.
7 employees
CEO: Nicholas Peter Karos
Universal Ibogaine Inc., a life sciences enterprise, focuses on developing, acquiring, and operating addiction treatment centers across Canada. The company is additionally preparing to launch clinical trials aimed at researching ibogaine...